Medmira Stock Performance
| MMIRF Stock | USD 0.01 0.00 0.00% |
The company secures a Beta (Market Risk) of 2.16, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MedMira will likely underperform. At this point, MedMira has a negative expected return of -0.43%. Please make sure to verify MedMira's information ratio, as well as the relationship between the kurtosis and relative strength index , to decide if MedMira performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days MedMira has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
MedMira |
MedMira Relative Risk vs. Return Landscape
If you would invest 5.00 in MedMira on October 30, 2025 and sell it today you would lose (3.80) from holding MedMira or give up 76.0% of portfolio value over 90 days. MedMira is currently producing negative expected returns and takes up 16.8932% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than MedMira, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MedMira Target Price Odds to finish over Current Price
The tendency of MedMira Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 85.92 |
Based on a normal probability distribution, the odds of MedMira to move above the current price in 90 days from now is about 85.92 (This MedMira probability density function shows the probability of MedMira Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 2.16 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, MedMira will likely underperform. Additionally MedMira has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. MedMira Price Density |
| Price |
Predictive Modules for MedMira
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MedMira. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.MedMira Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MedMira is not an exception. The market had few large corrections towards the MedMira's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MedMira, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MedMira within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.56 | |
β | Beta against Dow Jones | 2.16 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | -0.03 |
MedMira Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MedMira for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MedMira can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MedMira generated a negative expected return over the last 90 days | |
| MedMira has high historical volatility and very poor performance | |
| MedMira has some characteristics of a very speculative penny stock | |
| MedMira has high likelihood to experience some financial distress in the next 2 years | |
| MedMira has accumulated 40 K in total debt. MedMira has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MedMira until it has trouble settling it off, either with new capital or with free cash flow. So, MedMira's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MedMira sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MedMira to invest in growth at high rates of return. When we think about MedMira's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 952.13 K. Net Loss for the year was (1.83 M) with loss before overhead, payroll, taxes, and interest of (512.51 K). | |
| MedMira has accumulated about 396.14 K in cash with (1.88 M) of positive cash flow from operations. | |
| Roughly 70.0% of the company outstanding shares are owned by corporate insiders |
MedMira Fundamentals Growth
MedMira Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MedMira, and MedMira fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedMira Pink Sheet performance.
| Return On Asset | -0.23 | |||
| Profit Margin | (2.27) % | |||
| Operating Margin | (1.79) % | |||
| Current Valuation | 36.69 M | |||
| Shares Outstanding | 697.45 M | |||
| Price To Earning | (3.72) X | |||
| Price To Sales | 36.63 X | |||
| Revenue | 952.13 K | |||
| EBITDA | (1.07 M) | |||
| Cash And Equivalents | 396.14 K | |||
| Total Debt | 40 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.88 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 3.83 M | |||
About MedMira Performance
By analyzing MedMira's fundamental ratios, stakeholders can gain valuable insights into MedMira's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedMira has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedMira has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, the Asia Pacific, and internationally. The company was founded in 1993 and is headquartered in Halifax, Canada. Medmira operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about MedMira performance evaluation
Checking the ongoing alerts about MedMira for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MedMira help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MedMira generated a negative expected return over the last 90 days | |
| MedMira has high historical volatility and very poor performance | |
| MedMira has some characteristics of a very speculative penny stock | |
| MedMira has high likelihood to experience some financial distress in the next 2 years | |
| MedMira has accumulated 40 K in total debt. MedMira has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MedMira until it has trouble settling it off, either with new capital or with free cash flow. So, MedMira's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MedMira sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MedMira to invest in growth at high rates of return. When we think about MedMira's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 952.13 K. Net Loss for the year was (1.83 M) with loss before overhead, payroll, taxes, and interest of (512.51 K). | |
| MedMira has accumulated about 396.14 K in cash with (1.88 M) of positive cash flow from operations. | |
| Roughly 70.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing MedMira's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedMira's stock is overvalued or undervalued compared to its peers.
- Examining MedMira's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedMira's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedMira's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedMira's pink sheet. These opinions can provide insight into MedMira's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MedMira Pink Sheet analysis
When running MedMira's price analysis, check to measure MedMira's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedMira is operating at the current time. Most of MedMira's value examination focuses on studying past and present price action to predict the probability of MedMira's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedMira's price. Additionally, you may evaluate how the addition of MedMira to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |